SE0401465D0 - New substituted piperdines as modulators of dopamine neurotransmission - Google Patents

New substituted piperdines as modulators of dopamine neurotransmission

Info

Publication number
SE0401465D0
SE0401465D0 SE0401465A SE0401465A SE0401465D0 SE 0401465 D0 SE0401465 D0 SE 0401465D0 SE 0401465 A SE0401465 A SE 0401465A SE 0401465 A SE0401465 A SE 0401465A SE 0401465 D0 SE0401465 D0 SE 0401465D0
Authority
SE
Sweden
Prior art keywords
piperdines
modulators
new substituted
dopamine neurotransmission
neurotransmission
Prior art date
Application number
SE0401465A
Other languages
English (en)
Swedish (sv)
Inventor
Clas Sonesson
Lars Swanson
Nicholas Waters
Original Assignee
Carlsson A Research Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsson A Research Ab filed Critical Carlsson A Research Ab
Priority to SE0401465A priority Critical patent/SE0401465D0/xx
Publication of SE0401465D0 publication Critical patent/SE0401465D0/xx
Priority to DE602005017780T priority patent/DE602005017780D1/de
Priority to CA002569842A priority patent/CA2569842A1/en
Priority to EP05750549A priority patent/EP1765779B1/de
Priority to AT05750549T priority patent/ATE449071T1/de
Priority to DK05750549.7T priority patent/DK1765779T3/da
Priority to JP2007526288A priority patent/JP2008501748A/ja
Priority to PCT/EP2005/006152 priority patent/WO2005121092A1/en
Priority to NZ552410A priority patent/NZ552410A/en
Priority to CN2005800231908A priority patent/CN101076517B/zh
Priority to AU2005251908A priority patent/AU2005251908B2/en
Priority to MXPA06013945A priority patent/MXPA06013945A/es
Priority to US11/567,886 priority patent/US7579474B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SE0401465A 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission SE0401465D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission
MXPA06013945A MXPA06013945A (es) 2004-06-08 2005-06-08 Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
AT05750549T ATE449071T1 (de) 2004-06-08 2005-06-08 Neue substituierte piperidine als modulatoren der dopamin neurotransmission
CA002569842A CA2569842A1 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
EP05750549A EP1765779B1 (de) 2004-06-08 2005-06-08 Neue substituierte piperidine als modulatoren der dopamin neurotransmission
DE602005017780T DE602005017780D1 (de) 2004-06-08 2005-06-08 Neue substituierte piperidine als modulatoren der dopamin neurotransmission
DK05750549.7T DK1765779T3 (da) 2004-06-08 2005-06-08 Nye substituerede piperidiner som modulatorer for dopamin-neurotransmission
JP2007526288A JP2008501748A (ja) 2004-06-08 2005-06-08 ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン
PCT/EP2005/006152 WO2005121092A1 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
NZ552410A NZ552410A (en) 2004-06-08 2005-06-08 New 4-phenyl-piperidin-4-ol derivatives as modulators of dopamine neurotransmission
CN2005800231908A CN101076517B (zh) 2004-06-08 2005-06-08 作为多巴胺神经传递调节剂的取代的哌啶类
AU2005251908A AU2005251908B2 (en) 2004-06-08 2005-06-08 New substituted piperidines as modulators of dopamine neurotransmission
US11/567,886 US7579474B2 (en) 2004-06-08 2006-12-07 Substituted piperidines as modulators of dopamine neurotransmission

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission

Publications (1)

Publication Number Publication Date
SE0401465D0 true SE0401465D0 (sv) 2004-06-08

Family

ID=32653560

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401465A SE0401465D0 (sv) 2004-06-08 2004-06-08 New substituted piperdines as modulators of dopamine neurotransmission

Country Status (7)

Country Link
US (1) US7579474B2 (de)
EP (1) EP1765779B1 (de)
CN (1) CN101076517B (de)
AU (1) AU2005251908B2 (de)
CA (1) CA2569842A1 (de)
SE (1) SE0401465D0 (de)
WO (1) WO2005121092A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101808987A (zh) 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
CN102224135A (zh) 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的新3-苯基-氮杂环丁烷衍生物
WO2010058020A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2010071575A1 (en) * 2008-12-16 2010-06-24 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
WO2011075470A1 (en) * 2009-12-15 2011-06-23 Astrazeneca Pharmaceuticals Lp Quaternary piperidine compounds and uses thereof
EP2787997A4 (de) 2011-12-08 2015-05-27 Ivax Int Gmbh Hydrobromidsalz von pridopidin
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
AU2017223838B2 (en) 2016-02-24 2022-09-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CA3035099C (en) * 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
IL302261A (en) * 2020-10-20 2023-06-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine and analogues for the treatment of anxiety and depression

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE662455A (de) * 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4048314A (en) * 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4333942A (en) * 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
EP0094159B1 (de) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridinderivate, deren Herstellung und Verwendung
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2157204T3 (es) 1991-04-17 2001-08-16 Upjohn Co Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina.
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2197451C (en) 1994-08-18 2001-01-23 Bertrand L. Chenard Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE69731070T2 (de) 1996-07-22 2005-03-17 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol und arylpiperidin-derivate und sie enthaltende arzneimittel
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
EP0846683B1 (de) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxypiperidinderivate
AU7206398A (en) 1997-05-14 1998-12-08 Neurosearch A/S Piperidine derivatives as neurotransmitter re-uptake inhibitors
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
EP1177792A3 (de) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamin-d4-ligande zur behandlung von gaudi-suchenden krankheiten
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
US6815448B2 (en) 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
JP2008501749A (ja) 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
JP4797021B2 (ja) 2004-10-01 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防用のジペプチジルペプチダ−ゼ−ｉｖ阻害剤としてのアミノピペリジン
MX2007004216A (es) 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
CN101076517B (zh) 2010-12-15
AU2005251908A1 (en) 2005-12-22
US20070270467A1 (en) 2007-11-22
EP1765779A1 (de) 2007-03-28
US7579474B2 (en) 2009-08-25
AU2005251908B2 (en) 2011-03-17
CA2569842A1 (en) 2005-12-22
EP1765779B1 (de) 2009-11-18
WO2005121092A1 (en) 2005-12-22
CN101076517A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
DK1948606T3 (da) 3, 5-disubstituerede phenyl-piperidiner som modulatorer af dopaminneurotransmission
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200700909A1 (ru) Азаиндолкарбоксамиды
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
TW200616637A (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
UA87853C2 (en) Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren